Navigation Links
SeraCare Life Sciences Divests Biorepository Business
Date:1/4/2013

Milford, Massachusetts (PRWEB) January 03, 2013

SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc. This Maryland-based business includes biorepository and biobanking services, AccuCell® products and certain laboratory services.

“The sale of our Biorepository business is an important element in our growth strategy for SeraCare,” said Charles Mamrak, CEO of SeraCare. “We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease.”

The transaction includes the transfer of Biorepository assets and employees. Financial terms of the transaction were not disclosed. SeraCare Life Sciences was advised by BroadOak Partners LLC and Kirkland & Ellis LLP during the transaction.

About SeraCare Life Sciences, Inc.
SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit http://www.seracare.com.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.

# # #

Read the full story at http://www.prweb.com/releases/2013/1/prweb10290264.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
2. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
3. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
4. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
5. 1DegreeBio Expands its Product Review Platform Across Life Sciences
6. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
7. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
8. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):